On February 13, 2024, Metagenomi, Inc., a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The shares began trading on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol “MGX.” The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.

Wilson Sonsini Goodrich & Rosati advised Metagenomi on patent matters related to the transaction. The Wilson Sonsini team includes Ali Alemozafar, Michael Hostetler, Derrick Rowe, Rachna Ujwal, Daria Lukasz, Danya Martell Smart, Joy Wang, Tina Xiang, Brandon Tavshanjian, and Kevin Tylock.

For more information, please see Metagenomi’s press release.